These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17183432)

  • 1. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.
    Ferrari-Lacraz S; Aubert V; Buhler L; Pascual M; Andresen I; Binet I; Martin PY; Villard J
    Swiss Med Wkly; 2006 Oct; 136(43-44):696-702. PubMed ID: 17183432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience.
    Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M
    Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates.
    Nair V; Sawinski D; Akalin E; Friedlander R; Ebcioglu Z; Sehgal V; Dinavahi R; Khaim R; Ames S; Lerner S; Murphy B; Bromberg JS; Heeger PS; Schröppel B
    Clin Transplant; 2012; 26(3):E261-8. PubMed ID: 22686949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different responses of human anti-HLA and anti-alphagal antibody to long-term intravenous immunoglobulin therapy.
    Bühler L; Pidwell D; Dowling RD; Newman D; Awwad M; Cooper DK
    Xenotransplantation; 1999 Aug; 6(3):181-6. PubMed ID: 10503784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation.
    Picascia A; Grimaldi V; Paolillo R; Vasco M; Casamassimi A; De Luca FP; Cavalca F; Schiano C; Napoli C
    Ren Fail; 2014 May; 36(4):585-8. PubMed ID: 24456257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients.
    Glotz D; Haymann JP; Sansonetti N; Francois A; Menoyo-Calonge V; Bariety J; Druet P
    Transplantation; 1993 Aug; 56(2):335-7. PubMed ID: 8356587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
    Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
    Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time?
    Kozlowski T; Andreoni K
    Ann Transplant; 2011; 16(2):19-25. PubMed ID: 21716181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
    Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
    Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients.
    John R; Lietz K; Burke E; Ankersmit J; Mancini D; Suciu-Foca N; Edwards N; Rose E; Oz M; Itescu S
    Circulation; 1999 Nov; 100(19 Suppl):II229-35. PubMed ID: 10567309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications.
    Jordan S; Cunningham-Rundles C; McEwan R
    Am J Transplant; 2003 Jun; 3(6):653-64. PubMed ID: 12780556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients.
    Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA
    Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.
    Ravindranath MH
    J Immunol Res; 2017; 2017():3475926. PubMed ID: 28634589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.